Please login to the form below

Not currently logged in
Email:
Password:

CSCC

This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

myasthenic syndrome (LEMS), Novimmune’s Gamifant (emapalumab) for primary hemophagocytic lymphohistiocytosis (HLH), Regeneron/Sanofi’s Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC), and SIGA Technologies’ TPOXX (tecovirimat)

Latest news

  • As France protests, Sanofi takes axe to 670 jobs As France protests, Sanofi takes axe to 670 jobs

    dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.

  • Dupixent helps put Sanofi back on growth track Dupixent helps put Sanofi back on growth track

    Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... Regeneron-partnered cemiplimab is the first of the

  • Sanofi’s PD-1 inhibitor starts EU review for skin cancer Sanofi’s PD-1 inhibitor starts EU review for skin cancer

    Sanofi has filed cemiplimab in the first instance as a treatment for advanced cutaneous squamous cell carcinoma (CSCC), which it says is the “deadliest form of non-melanoma skin cancer”. ... As of yet, none of the other PD-1/PD-L1-targeting drugs are

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    CSCC is the second deadliest skin cancer after melanoma, and while quite treatable if caught early it is very serious in the advanced stages. ... Advanced CSCC is responsible for 3, 900 to 8, 800 deaths per year in the US,” said Regeneron’s clinical

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics